Cyclacel Pharmaceuticalsincis A Clinical Stage Biopharmaceutical Company Based In Berkeley Heightsnew Jerseyfounded In 1996The Company Focuses On Developing Innovative Cancer Medicines Through Its Expertise In Cell Cycletranscriptional Regulationepigeneticsand Mitosis Biologycyclacel Is Advancing A Diverse Pipeline Of Drug Candidatesincluding Fadraciclibcyc065 An Inhibitor Of Cyclin Dependent Kinases Currently In Phase 1 2 Trials For Advanced Solid Tumorsand Oral Sapacitabinewhich Is In Phase 2 Trials For Acute Myeloid Leukemiathe Company Is Also Developing Cyc140A Polo Like Kinase 1 Inhibitor In Preclinical Stagescyclacel Collaborates With Leading Cancer Research Institutions To Enhance Its Clinical Programs And Retains Marketing Rights To Its Drug Programsplanning Future Partnerships To Maximize Commercial Opportunities
